vtioВестник трансплантологии и искусственных органовRussian Journal of Transplantology and Artificial Organs1995-1191Academician V.I.Shumakov National Medical Research Center of Transplantology and Artificial Organs", Ministry of Health of the Russian Federation10.15825/1995-1191-2024-2-42-47vtio-1764Research ArticleТрансплантация сердца и вспомогательное кровообращениеHeart Transplantation and Assisted CirculationВаскулопатия трансплантата сердца – состояние проблемыCardiac allograft vasculopathy: current reviewМиронковБ. Л.MironkovB. L.

Москва

Moscow

УвароваД. Д.UvarovaD. D.

Москва

Moscow

КолосковаН. Н.KoloskovaN. N.

Москва

Moscow

СапроноваЮ. В.SapronovaYu. V.

Москва

Moscow

МуминовИ. И.MuminovI. I.

Москва

Moscow

ЮсоваА. А.YusovaA. A.

Москва

Moscow

СаховскийС. А.SakhovskyS. A.

Саховский Степан Анатольевич

123182, Москва, ул. Щукинская, д. 1

Тел. (926) 636-00-31

Stepan Sakhovsky

1, Shchukinskaya str., Moscow, 123182

Phone: (926) 636-00-31

Milifolium@gmail.comФГБУ «Национальный медицинский исследовательский центр трансплантологии и искусственных органов имени академика В.И. Шумакова» Минздрава РоссииShumakov National Medical Research Center of Transplantology and Artificial Organs2024190320242624247Copyright © Миронков Б.Л., Уварова Д.Д., Колоскова Н.Н., Сапронова Ю.В., Муминов И.И., Юсова А.А., Саховский С.А., 20242024Миронков Б.Л., Уварова Д.Д., Колоскова Н.Н., Сапронова Ю.В., Муминов И.И., Юсова А.А., Саховский С.А.Mironkov B.L., Uvarova D.D., Koloskova N.N., Sapronova Y.V., Muminov I.I., Yusova A.A., Sakhovsky S.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.transpl.ru/vtio/article/view/1764

Коронарная патология пересаженного сердца является одной из основных причин дисфункции трансплантата и его потери. Своевременная диагностика и лечение васкулопатии пересаженного сердца позволяют увеличить выживаемость трансплантата и улучшить прогноз для реципиентов сердца. В данном обзоре представлены актуальные данные по проблеме васкулопатии трансплантата сердца, его патогенезе и основных факторах, влияющих на течение данного заболевания.

Transplant coronary artery disease (TCAD) is one of the main causes of graft dysfunction and graft loss. Early diagnosis and treatment of cardiac allograft vasculopathy (CAV) can increase graft survival and improve the prognosis for heart transplant recipients. This review presents current data on the problem of CAV, its pathogenesis and the main factors influencing the course of this disease.

васкулопатия трансплантата сердцатрансплантация сердцаcardiac allograft vasculopathyheart transplantationReferencesГотье СВ, Хомяков СМ. Донорство и трансплантация органов в Российской Федерации в 2022 году. XV сообщение регистра Российского трансплантологического общества. Вестник трансплантологии и искусственных органов. 2023; 25 (3): 8–30. https://doi.org/10.15825/1995-1191-20233-8-30.Gautier SV, Khomyakov SM. Organ donation and transplantation in the Russian Federation in 2022. 15th Report from the Registry of the Russian Transplant Society. Russian Journal of Transplantology and Artificial Organs. 2023; 25 (3): 8–30. https://doi.org/10.15825/1995-1191-20233-8-30.Khush KK, Cherikh WS, Chambers DC, Harhay MO, Hayes D Jr, Hsich E et al. The international thoracic organ transplant registry of the international society for heart and lung transplantation: thirty-sixth adult heart transplantation report – 2019. J Heart Lung Transplant. 2019; 38 (10): 1056–1066. doi: 10.1016/j.healun.2019.08.004.Khush KK, Cherikh WS, Chambers DC, Harhay MO, Hayes D Jr, Hsich E et al. The international thoracic organ transplant registry of the international society for heart and lung transplantation: thirty-sixth adult heart transplantation report – 2019. J Heart Lung Transplant. 2019; 38 (10): 1056–1066. doi: 10.1016/j.healun.2019.08.004.Shah KS, Kittleson MM, Kobashigawa JA. Updates on Heart Transplantation. Curr Heart Fail Rep. 2019 Oct; 16 (5): 150–156. doi: 10.1007/s11897-019-00432-3.Shah KS, Kittleson MM, Kobashigawa JA. Updates on Heart Transplantation. Curr Heart Fail Rep. 2019 Oct; 16 (5): 150–156. doi: 10.1007/s11897-019-00432-3.Shetty M, Chowdhury YS. Heart Transplantation Allograft Vasculopathy. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2023.Shetty M, Chowdhury YS. Heart Transplantation Allograft Vasculopathy. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2023.Lee F, Nair V, Chih S. Cardiac allograft vasculopathy: Insights on pathogenesis and therapy. Clin Transplant. 2020 Mar; 34 (3): e13794. doi: 10.1111/ctr.13794.Lee F, Nair V, Chih S. Cardiac allograft vasculopathy: Insights on pathogenesis and therapy. Clin Transplant. 2020 Mar; 34 (3): e13794. doi: 10.1111/ctr.13794.Spitaleri G, Farrero Torres M, Sabatino M, Potena L. The pharmaceutical management of cardiac allograft vasculopathy after heart transplantation. Expert Opin Pharmacother. 2020; 21 (11): 1367–1376.Spitaleri G, Farrero Torres M, Sabatino M, Potena L. The pharmaceutical management of cardiac allograft vasculopathy after heart transplantation. Expert Opin Pharmacother. 2020; 21 (11): 1367–1376.Spartalis M, Spartalis E, Siasos G. Cardiac allograft vasculopathy after heart transplantation: Pathophysiology, detection approaches, prevention, and treatment management. Trends Cardiovasc Med. 2022 Aug; 32 (6): 333–338. doi: 10.1016/j.tcm.2021.07.002.Spartalis M, Spartalis E, Siasos G. Cardiac allograft vasculopathy after heart transplantation: Pathophysiology, detection approaches, prevention, and treatment management. Trends Cardiovasc Med. 2022 Aug; 32 (6): 333–338. doi: 10.1016/j.tcm.2021.07.002.Rahmani M, Cruz RP, Granville DJ, McManus BM. Allograft vasculopathy versus atherosclerosis. Circ Res. 2006 Oct 13; 99 (8): 801–815. doi: 10.1161/01.RES.0000246086.93555.f3.Rahmani M, Cruz RP, Granville DJ, McManus BM. Allograft vasculopathy versus atherosclerosis. Circ Res. 2006 Oct 13; 99 (8): 801–815. doi: 10.1161/01.RES.0000246086.93555.f3.Hu D, Yin C, Luo S, Habenicht AJR, Mohanta SK. Vascular Smooth Muscle Cells Contribute to Atherosclerosis Immunity. Front Immunol. 2019 May 17; 10: 1101. doi: 10.3389/fimmu.2019.01101.Hu D, Yin C, Luo S, Habenicht AJR, Mohanta SK. Vascular Smooth Muscle Cells Contribute to Atherosclerosis Immunity. Front Immunol. 2019 May 17; 10: 1101. doi: 10.3389/fimmu.2019.01101.Doulamis IP. Editorial commentary: Cardiac allograft vasculopathy: Caveats and perspectives. Trends Cardiovasc Med. 2022; 32 (6): 339–340. doi: 10.1016/j.tcm.2021.07.007.Doulamis IP. Editorial commentary: Cardiac allograft vasculopathy: Caveats and perspectives. Trends Cardiovasc Med. 2022; 32 (6): 339–340. doi: 10.1016/j.tcm.2021.07.007.Болезнь коронарных артерий пересаженного сердца. Под ред. В.И. Шумакова. М.: МИА, 2008; 160. https://www.centrmag.ru/catalog/product/bolezn-koronarnyh-arterij-peresazhennogo-serdca/ (accessed: 17.10.2023).Bolezn’ koronarnykh arteriy peresazhennogo serdtsa. Pod red. V.I. Shumakova. M.: MIA, 2008; 160. [Electronic resource]. https://www.centrmag.ru/catalog/product/bolezn-koronarnyh-arterij-peresazhennogo-serdca/ (accessed: 17.10.2023).Alyaydin E, Welp H, Reinecke H, Tuleta I. Predisposing factors for late mortality in heart transplant patients. Cardiol J. 2021; 28 (5): 746–757. doi: 10.5603/CJ.a2020.0011.Alyaydin E, Welp H, Reinecke H, Tuleta I. Predisposing factors for late mortality in heart transplant patients. Cardiol J. 2021; 28 (5): 746–757. doi: 10.5603/CJ.a2020.0011.Guzik B, Szczepanek E, Niewiara Ł, Nosal M, Wierzbicki K, Krzanowski M et al. Coronary revascularization after heart transplant – the search for prognostic factors. Arch Med Sci. 2020 Apr 18; 16 (4): 789–795. doi: 10.5114/aoms.2017.71847.Guzik B, Szczepanek E, Niewiara Ł, Nosal M, Wierzbicki K, Krzanowski M et al. Coronary revascularization after heart transplant – the search for prognostic factors. Arch Med Sci. 2020 Apr 18; 16 (4): 789–795. doi: 10.5114/aoms.2017.71847.Foroutan F, Alba AC, Guyatt G, Duero Posada J, Ng Fat Hing N, Arseneau E et al. Predictors of 1-year mortality in heart transplant recipients: a systematic review and meta-analysis. Heart. 2018 Jan; 104 (2): 151–160. doi: 10.1136/heartjnl-2017-311435.Foroutan F, Alba AC, Guyatt G, Duero Posada J, Ng Fat Hing N, Arseneau E et al. Predictors of 1-year mortality in heart transplant recipients: a systematic review and meta-analysis. Heart. 2018 Jan; 104 (2): 151–160. doi: 10.1136/heartjnl-2017-311435.Саховский СА, Изотов ДА, Гончарова АЮ, Колоскова НН, Миронков БЛ. Коронарный атеросклероз донорского сердца. Всероссийская научно-практическая конференция с международным участием «Комплексные проблемы сердечно-сосудистых заболеваний». 2021; S2: 166. https://cyberleninka.ru/article/n/koronarnyy-ateroskleroz-donorskogo-serdtsa (дата обращения: 12.01.2024).Sakhovskiy SA, Izotov DA, Goncharova AYu, Koloskova NN, Mironkov BL. Koronarnyy ateroskleroz donorskogo serdtsa. Vserossiyskaya nauchno-prakticheskaya konferentsiya s mezhdunarodnym uchastiem «Kompleksnye problemy serdechno-sosudistykh zabolevaniy». 2021; S2: 166. https://cyberleninka.ru/article/n/koronarnyy-ateroskleroz-donorskogo-serdtsa (дата обращения: 12.01.2024).Stehlik J, Kobashigawa J, Hunt SA, Reichenspurner H, Kirklin JK. Honoring 50 Years of Clinical Heart Transplantation in Circulation: In-Depth State-of-the-Art Review. Circulation. 2018 Jan 2; 137 (1): 71–87. doi: 10.1161/CIRCULATIONAHA.117.029753.Stehlik J, Kobashigawa J, Hunt SA, Reichenspurner H, Kirklin JK. Honoring 50 Years of Clinical Heart Transplantation in Circulation: In-Depth State-of-the-Art Review. Circulation. 2018 Jan 2; 137 (1): 71–87. doi: 10.1161/CIRCULATIONAHA.117.029753.Lu WH, Palatnik K, Fishbein GA, Lai C, Levi DS, Perens G et al. Diverse morphologic manifestations of cardiac allograft vasculopathy: a pathologic study of 64 allograft hearts. J Heart Lung Transplant. 2011 Sep; 30 (9): 1044–1050. doi: 10.1016/j.healun.2011.04.008.Lu WH, Palatnik K, Fishbein GA, Lai C, Levi DS, Perens G et al. Diverse morphologic manifestations of cardiac allograft vasculopathy: a pathologic study of 64 allograft hearts. J Heart Lung Transplant. 2011 Sep; 30 (9): 1044–1050. doi: 10.1016/j.healun.2011.04.008.Можейко НП. Патоморфология трансплантированного сердца: дис. … докт. мед. наук. М., 2020; 171. https://freereferats.ru/product_info.php?products_id=691983 (accessed: 17.10.2023).Mozheyko NP. Patomorfologiya transplantirovannogo serdtsa: dis. … dokt. med. nauk. M., 2020; 171. [Electronic resource]. https://freereferats.ru/product_info.php?products_id=691983 (accessed: 17.10.2023).Муминов ИИ, Колоскова НН, Попцов ВН, Захаревич ВМ, Можейко НП, Саховский СА, Шевченко АО. Опыт амбулаторного наблюдения реципиентов после трансплантации сердца в НМИЦ ТИО имени академика В.И. Шумакова. Вестник трансплантологии и искусственных органов. 2023; 25 (3): 68–75. https://doi.org/10.15825/1995-1191-2023-3-68-75.Muminov II, Koloskova NN, Poptsov VN, Zakharevich VM, Mozheiko NP, Sakhovsky SA, Shevchenko AO. Experience of outpatient follow-up of heart transplant recipients at Shumakov center. Russian Journal of Transplantology and Artificial Organs. 2023; 25 (3): 68–75. https://doi.org/10.15825/1995-1191-2023-3-68-75.Саховский СА, Уварова ДД, Миронков БЛ. Течение коронарной патологии у реципиентов сердца с гемодинамически не значимым трансмиссивным атеросклерозом. Вестник трансплантологии и искусственных органов. 2023; 25 (S): 46.Sakhovskiy SA, Uvarova DD, Mironkov BL. Techenie koronarnoy patologii u retsipientov serdtsa s gemodinamicheski ne znachimym transmissivnym aterosklerozom. Russian Journal of Transplantology and Artificial Organs. 2023; 25 (S): 46.Саховский СА, Колоскова НН, Изотов ДА, Спирина ЕА, Гончарова АЮ, Лучкин ВМ, Миронков БЛ. Оценка продолжительности жизни реципиентов сердца с трансмиссивным атеросклерозом коронарных артерий. Вестник трансплантологии и искусственных органов. 2019; 21 (4): 14–19. https://doi.org/10.15825/1995-1191-2019-4-14-19.Sakhovsky SA, Koloskova NN, Izotov DA, Spirina EA, Goncharova AYu, Luchkin VM, Mironkov BL. Life expectancy of heart recipients with donor-transmitted coronary atherosclerosis. Russian Journal of Transplantology and Artificial Organs. 2019; 21 (4): 14–19. https://doi.org/10.15825/1995-1191-2019-4-14-19.Честухин ВВ, Остроумов ЕН, Тюняева ИЮ, Захаревич ВМ и др. Болезнь коронарных артерий пересаженного сердца. Возможности диагностики и лечения. Очерки клинической трансплантологии. Под ред. С.В. Готье. М., 2009: 88–93.Chestukhin VV, Ostroumov EN, Tyunyaeva IYu, Zakharevich VM i dr. Bolezn’ koronarnykh arteriy peresazhennogo serdtsa. Vozmozhnosti diagnostiki i lecheniya. Ocherki klinicheskoy transplantologii. Pod red S.V. Gautier. М., 2009: 88–93.Готье СВ, Шевченко АО, Попцов ВН. Пациент с трансплантированным сердцем: руководство для врачей по ведению пациентов, перенесших трансплантацию сердца. М.–Тверь: Триада, 2014; 144.Gautier SV, Shevchenko AO, Poptsov VN. Patsient s transplantirovannym serdtsem: rukovodstvo dlya vrachey po vedeniyu patsientov, perenesshikh transplantatsiyu serdtsa. M.–Tver’: Triada, 2014; 144.Velleca A, Shullo MA, Dhital K, Azeka E, Colvin M, DePasquale E et al. The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2023 May; 42 (5): e1–e141. doi: 10.1016/j.healun.2022.10.015.Velleca A, Shullo MA, Dhital K, Azeka E, Colvin M, DePasquale E et al. The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2023 May; 42 (5): e1–e141. doi: 10.1016/j.healun.2022.10.015.Raichlin E, Bae JH, Kushwaha SS, Lennon RJ, Prasad A, Rihal CS, Lerman A. Inflammatory burden of cardiac allograft coronary atherosclerotic plaque is associated with early recurrent cellular rejection and predicts a higher risk of vasculopathy progression. J Am Coll Cardiol. 2009 Apr 14; 53 (15): 1279–1286. doi: 10.1016/j.jacc.2008.12.041.Raichlin E, Bae JH, Kushwaha SS, Lennon RJ, Prasad A, Rihal CS, Lerman A. Inflammatory burden of cardiac allograft coronary atherosclerotic plaque is associated with early recurrent cellular rejection and predicts a higher risk of vasculopathy progression. J Am Coll Cardiol. 2009 Apr 14; 53 (15): 1279–1286. doi: 10.1016/j.jacc.2008.12.041.Pighi M, Gratta A, Marin F, Bellamoli M, Lunardi M, Fezzi S et al. Cardiac allograft vasculopathy: Pathogenesis, diagnosis and therapy. Transplant Rev (Orlando). 2020 Oct; 34 (4): 100569. doi: 10.1016/j.trre.2020.100569.Pighi M, Gratta A, Marin F, Bellamoli M, Lunardi M, Fezzi S et al. Cardiac allograft vasculopathy: Pathogenesis, diagnosis and therapy. Transplant Rev (Orlando). 2020 Oct; 34 (4): 100569. doi: 10.1016/j.trre.2020.100569.Peled Y, Lavee J, Raichlin E, Katz M, Arad M, Kassif Y et al. Early aspirin initiation following heart transplantation is associated with reduced risk of allograft vasculopathy during long-term follow-up. Clin Transplant. 2017 Dec; 31 (12). doi: 10.1111/ctr.13133.Peled Y, Lavee J, Raichlin E, Katz M, Arad M, Kassif Y et al. Early aspirin initiation following heart transplantation is associated with reduced risk of allograft vasculopathy during long-term follow-up. Clin Transplant. 2017 Dec; 31 (12). doi: 10.1111/ctr.13133.Vallakati A, Reddy S, Dunlap ME, Taylor DO. Impact of Statin Use After Heart Transplantation: A Meta-Analysis. Circ Heart Fail. 2016 Oct; 9 (10): e003265. doi: 10.1161/CIRCHEARTFAILURE.116.003265.Vallakati A, Reddy S, Dunlap ME, Taylor DO. Impact of Statin Use After Heart Transplantation: A Meta-Analysis. Circ Heart Fail. 2016 Oct; 9 (10): e003265. doi: 10.1161/CIRCHEARTFAILURE.116.003265.Fang JC, Kinlay S, Beltrame J, Hikiti H, Wainstein M, Behrendt D et al. Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: a randomised trial. Lancet. 2002 Mar 30; 359 (9312): 1108– 1113. doi: 10.1016/S0140-6736(02)08154-0.Fang JC, Kinlay S, Beltrame J, Hikiti H, Wainstein M, Behrendt D et al. Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: a randomised trial. Lancet. 2002 Mar 30; 359 (9312): 1108– 1113. doi: 10.1016/S0140-6736(02)08154-0.Mallah SI, Atallah B, Moustafa F, Naguib M, El Hajj S, Bader F, Mehra MR. Evidence-based pharmacotherapy for prevention and management of cardiac allograft vasculopathy. Prog Cardiovasc Dis. 2020 May-Jun; 63 (3): 194–209. doi: 10.1016/j.pcad.2020.03.007.Mallah SI, Atallah B, Moustafa F, Naguib M, El Hajj S, Bader F, Mehra MR. Evidence-based pharmacotherapy for prevention and management of cardiac allograft vasculopathy. Prog Cardiovasc Dis. 2020 May-Jun; 63 (3): 194–209. doi: 10.1016/j.pcad.2020.03.007.Masetti M, Potena L, Nardozza M, Prestinenzi P, Taglieri N, Saia F et al. Differential effect of everolimus on progression of early and late cardiac allograft vasculopathy in current clinical practice. Am J Transplant. 2013 May; 13 (5): 1217–1226. doi: 10.1111/ajt.12208.Masetti M, Potena L, Nardozza M, Prestinenzi P, Taglieri N, Saia F et al. Differential effect of everolimus on progression of early and late cardiac allograft vasculopathy in current clinical practice. Am J Transplant. 2013 May; 13 (5): 1217–1226. doi: 10.1111/ajt.12208.Bellumkonda L, Patel J. Recent advances in the role of mammalian target of rapamycin inhibitors on cardiac allograft vasculopathy. Clin Transplant. 2020 Jan; 34 (1): e13769. doi: 10.1111/ctr.13769.Bellumkonda L, Patel J. Recent advances in the role of mammalian target of rapamycin inhibitors on cardiac allograft vasculopathy. Clin Transplant. 2020 Jan; 34 (1): e13769. doi: 10.1111/ctr.13769.

The authors declare that there are no conflicts of interest present.